Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Treasury Shares (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Treasury Shares for 7 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 144979.91% to $2.2 million in Q4 2025 year-over-year; TTM through Nov 2025 was $2.2 million, a 144979.91% increase, with the full-year FY2025 number at $2.2 million, up 144979.91% from a year prior.
  • Treasury Shares was $2.2 million for Q4 2025 at Nurix Therapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.0 million in Q1 2025 to a low of $971.0 in Q1 2021.
  • A 5-year average of $1.3 million and a median of $1.3 million in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: tumbled 99.9% in 2024, then skyrocketed 195381.91% in 2025.
  • Nurix Therapeutics' Treasury Shares stood at $971.0 in 2021, then skyrocketed by 80726.36% to $784824.0 in 2022, then soared by 58.77% to $1.2 million in 2023, then tumbled by 99.88% to $1548.0 in 2024, then skyrocketed by 144979.91% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Treasury Shares are $2.2 million (Q4 2025), $2.7 million (Q3 2025), and $3.0 million (Q2 2025).